시장보고서

상품코드

1631519

위암 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료 유형별, 질환 적응증별, 투여 경로별, 약제 클래스별, 지역별, 부문 예측(2025-2030년)

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Standard Chemotherapy), By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2024년 12월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

위암 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 위암 치료 시장 규모는 2030년까지 111억 9,000만 달러에 달할 것으로 추정되며, 2025-2030년에 12.5%의 CAGR로 성장할 전망입니다. 면역요법 및 분자 표적 치료의 보급과 신약 출시가 성장을 가속할 것으로 예상됩니다.

Globocan에 따르면 2020년 위암 발병률은 약 110만 명이며, 2030년에는 142만 명으로 증가할 것으로 예상됩니다. 질병의 분자적 기초에 대한 지식이 증가함에 따라 개발되어 시장에 출시되는 표적치료제 및 면역치료제의 수가 증가하고 있습니다. 허셉틴과 같은 HER-2 표적치료제는 2010년부터 시판되고 있습니다. 또한 VEGF를 표적으로 하는 모노클로널 항체 사이람자는 2014년부터 출시되었으며, EGFR과 PD-1을 표적으로 하는 약물과 면역치료제는 현재 위암 치료제로 개발되고 있습니다.

임상 파이프라인에 있는 약물의 승인 및 출시도 위암 치료제 시장을 촉진할 것으로 예상됩니다. 예를 들어 2021년 3월 NMPA는 Eli Lilly와 Innovent Biologics의 PD-1 억제제 신틸리맙(Sintilimab)을 위암 또는 위식도 접합부 선암 치료제로 중국에서 승인했습니다. 또한 2020년 5월 미국 FDA는 위암 치료제로 엔헬투를 희귀질환 치료제로 지정했습니다. 이후 2021년 1월 미국 FDA는 엔헬투를 진행성 또는 전이성 위암 치료제로 승인했습니다.

허셉틴과 같은 주요 약물의 특허 만료와 그에 따른 바이오시밀러 출시는 위암 치료제 시장의 성장을 억제할 것으로 예상됩니다. 또한 높은 비용으로 인해 표적 치료제의 채택이 적은 것도 시장 성장을 저해할 수 있습니다. 예를 들어 사이람자는 다른 약제에 비해 비용 효율성이 낮다고 여겨졌습니다. 영국에서는 NICE에서 비용 효율성이 낮다는 이유로 기각되었습니다. 또한 프랑스에서는 임상적으로 관련성이 있는 비교약과 비교했을 때 다른 혜택이 없습니다는 이유로 급여가 거부되었습니다.

위암 치료 시장 보고서 하이라이트

표적치료제는 2024년 39.6%의 점유율을 차지하며 시장을 장악할 것으로 예상됩니다. 표적치료제는 인접한 건강한 조직에 대한 피해를 최소화하면서 암세포를 정확하게 표적으로 삼는 치료법입니다.
위암/위식도 접합부가 2024년 매출 점유율 84.7%으로 시장을 주도했습니다.
주사 요법은 빠른 치료 효과와 화학요법 및 표적 요법을 혈류에 직접 투여하는 효과로 인해 2024년 89.0% 최대 매출 점유율을 차지할 것으로 예상됩니다.
VEGFR 길항제는 종양 성장과 전이에 필수적인 과정인 종양 혈관신생을 억제하는 중요한 역할로 인해 2024년 상당한 점유율을 차지할 것으로 예상됩니다.

지역별 시장 점유율 분석, 2024년 및 2030년
지역 시장 대시보드
시장 규모, 예측 동향 분석, 2018-2030년 :
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 덴마크
- 스웨덴
아시아태평양
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제9장 경쟁 구도

참가자 개요
기업의 시장 현황 분석
기업 분류
전략 지도제작
기업 개요/상장기업
- Novartis AG
- Pfizer Inc.
- Mylan NV
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Merck &Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- CELLTRION INC.
- Samsung Bioepis
- Bristol-Myers Squibb Company

KSA 25.02.07

Stomach Cancer Treatment Market Growth & Trends:

The global stomach cancer treatment market size is estimated to reach USD 11.19 billion by 2030, registering to grow at a CAGR of 12.5% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics' drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

Stomach Cancer Treatment Market Report Highlights:

Targeted therapy dominated the market and accounted for a share of 39.6% in 2024. Targeted therapy offers precision targeting cancer cells while minimizing harm to adjacent healthy tissues.
Gastric cancer/gastroesophageal junction led the market with a revenue share of 84.7% in 2024, fueled by its considerable prevalence and associated mortality rates worldwide.
Injectable treatment held the largest revenue share of 89.0% in 2024, aided by their rapid therapeutic action and effectiveness in administering chemotherapy and targeted therapies directly into the bloodstream.
VEGFR antagonists held a substantial share in 2024 due to their critical role in inhibiting tumor angiogenesis, a vital process for tumor growth and metastasis.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Treatment Type
- 1.2.2. Disease Indication
- 1.2.3. Route of Administration
- 1.2.4. Drug Class
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Stomach Cancer Treatment Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Stomach Cancer Treatment Market: Treatment Type Business Analysis

4.1. Treatment Type Market Share, 2024 & 2030
4.2. Treatment Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2018 to 2030 (USD Million)
4.4. Standard Chemotherapy
- 4.4.1. Standard Chemotherapy Market, 2018 - 2030 (USD Million)
4.5. Targeted Therapy
- 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
4.6. Immunotherapy
- 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)

Chapter 5. Stomach Cancer Treatment Market: Disease Indication Business Analysis

5.1. Disease Indication Market Share, 2024 & 2030
5.2. Disease Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
5.4. Gastric Cancer/Gastroesophageal Junction Cancer
- 5.4.1. Gastric Cancer/Gastroesophageal Junction Cancer Market, 2018 - 2030 (USD Million)
5.5. Gastrointestinal Stromal Tumors
- 5.5.1. Gastrointestinal Stromal Tumors Market, 2018 - 2030 (USD Million)

Chapter 6. Stomach Cancer Treatment Market: Route of Administration Business Analysis

6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Oral
- 6.4.1. Oral Market, 2018 - 2030 (USD Million)
6.5. Injectable
- 6.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 7. Stomach Cancer Treatment Market: Drug Class Business Analysis

7.1. Drug Class Market Share, 2024 & 2030
7.2. Drug Class Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
7.4. PD-1/PD-L1 Inhibitors
- 7.4.1. PD-1/PD-L1 Inhibitors Market, 2018 - 2030 (USD Million)
7.5. HER2 Antagonists
- 7.5.1. HER2 Antagonists Market, 2018 - 2030 (USD Million)
7.6. VEGFR Antagonists
- 7.6.1. VEGFR Antagonists Market, 2018 - 2030 (USD Million)
7.7 Others
- 7.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Stomach Cancer Treatment Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
- 8.4.1. North America Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Regulatory Framework
  - 8.4.2.3. Competitive Insights
  - 8.4.2.4. U.S. Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Regulatory Framework
  - 8.4.3.3. Competitive Insights
  - 8.4.3.4. Canada Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Regulatory Framework
  - 8.4.4.3. Competitive Insights
  - 8.4.4.4. Mexico Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
- 8.5.1. Europe Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Regulatory Framework
  - 8.5.2.3. Competitive Insights
  - 8.5.2.4. UK Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Regulatory Framework
  - 8.5.3.3. Competitive Insights
  - 8.5.3.4. Germany Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Regulatory Framework
  - 8.5.4.3. Competitive Insights
  - 8.5.4.4. France Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Regulatory Framework
  - 8.5.5.3. Competitive Insights
  - 8.5.5.4. Italy Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Regulatory Framework
  - 8.5.6.3. Competitive Insights
  - 8.5.6.4. Spain Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. Norway
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Regulatory Framework
  - 8.5.7.3. Competitive Insights
  - 8.5.7.4. Norway Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.8. Denmark
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Regulatory Framework
  - 8.5.8.3. Competitive Insights
  - 8.5.8.4. Denmark Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.9. Sweden
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. Regulatory Framework
  - 8.5.9.3. Competitive Insights
  - 8.5.9.4. Sweden Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Regulatory Framework
  - 8.6.2.3. Competitive Insights
  - 8.6.2.4. Japan Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Regulatory Framework
  - 8.6.3.3. Competitive Insights
  - 8.6.3.4. China Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Regulatory Framework
  - 8.6.4.3. Competitive Insights
  - 8.6.4.4. India Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. South Korea
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Regulatory Framework
  - 8.6.5.3. Competitive Insights
  - 8.6.5.4. South Korea Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.6. Australia
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Regulatory Framework
  - 8.6.6.3. Competitive Insights
  - 8.6.6.4. Australia Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. Regulatory Framework
  - 8.6.7.3. Competitive Insights
  - 8.6.7.4. Thailand Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Regulatory Framework
  - 8.7.2.3. Competitive Insights
  - 8.7.2.4. Brazil Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Regulatory Framework
  - 8.7.3.3. Competitive Insights
  - 8.7.3.4. Argentina Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
- 8.8.1. MEA Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Regulatory Framework
  - 8.8.2.3. Competitive Insights
  - 8.8.2.4. South Africa Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Regulatory Framework
  - 8.8.3.3. Competitive Insights
  - 8.8.3.4. Saudi Arabia Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Regulatory Framework
  - 8.8.4.3. Competitive Insights
  - 8.8.4.4. UAE Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Regulatory Framework
  - 8.8.5.3. Competitive Insights
  - 8.8.5.4. Kuwait Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
- 9.5.1. Novartis AG
  - 9.5.1.1. Overview
  - 9.5.1.2. Financial Performance
  - 9.5.1.3. Product Benchmarking
  - 9.5.1.4. Strategic Initiatives
- 9.5.2. Pfizer Inc.
  - 9.5.2.1. Overview
  - 9.5.2.2. Financial Performance
  - 9.5.2.3. Product Benchmarking
  - 9.5.2.4. Strategic Initiatives
- 9.5.3. Mylan N.V.
  - 9.5.3.1. Overview
  - 9.5.3.2. Financial Performance
  - 9.5.3.3. Product Benchmarking
  - 9.5.3.4. Strategic Initiatives
- 9.5.4. F. Hoffmann-La Roche Ltd
  - 9.5.4.1. Overview
  - 9.5.4.2. Financial Performance
  - 9.5.4.3. Product Benchmarking
  - 9.5.4.4. Strategic Initiatives
- 9.5.5. Eli Lilly and Company
  - 9.5.5.1. Overview
  - 9.5.5.2. Financial Performance
  - 9.5.5.3. Product Benchmarking
  - 9.5.5.4. Strategic Initiatives
- 9.5.6. Merck & Co., Inc.
  - 9.5.6.1. Overview
  - 9.5.6.2. Financial Performance
  - 9.5.6.3. Product Benchmarking
  - 9.5.6.4. Strategic Initiatives
- 9.5.7. Teva Pharmaceutical Industries Ltd.
  - 9.5.7.1. Overview
  - 9.5.7.2. Financial Performance
  - 9.5.7.3. Product Benchmarking
  - 9.5.7.4. Strategic Initiatives
- 9.5.8. CELLTRION INC.
  - 9.5.8.1. Overview
  - 9.5.8.2. Financial Performance
  - 9.5.8.3. Product Benchmarking
  - 9.5.8.4. Strategic Initiatives
- 9.5.9. Samsung Bioepis
  - 9.5.9.1. Overview
  - 9.5.9.2. Financial Performance
  - 9.5.9.3. Product Benchmarking
  - 9.5.9.4. Strategic Initiatives
- 9.5.10. Bristol-Myers Squibb Company
  - 9.5.10.1. Overview
  - 9.5.10.2. Financial Performance
  - 9.5.10.3. Product Benchmarking
  - 9.5.10.4. Strategic Initiatives

위암 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료 유형별, 질환 적응증별, 투여 경로별, 약제 클래스별, 지역별, 부문 예측(2025-2030년)

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Standard Chemotherapy), By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030

위암 치료 시장의 성장과 동향 :

위암 치료 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 개요

제3장 위암 치료 시장의 변수, 동향, 범위

제4장 위암 치료 시장 : 치료 유형별 비즈니스 분석

제5장 위암 치료 시장 : 질환 적응증별 비즈니스 분석

제6장 위암 치료 시장 : 투여 경로별 비즈니스 분석

제7장 위암 치료 시장 : 약제 클래스 비즈니스 분석

제8장 위암 치료 시장 : 지역 추정·동향 분석